AbbVie Submits FDA Application for Subcutaneous Version of Skyrizi
AbbVie has submitted an application to the US FDA for approval of a subcutaneous version of its drug Skyrizi (risankizumab), which is considered a more convenient method of administration. The application is backed by data from the phase 3 AFFIRM trial, which could impact AbbVie's market position in the biopharmaceutical sector.
Tickers: $ABBV
Topics: AbbVie drug approval pharmaceuticals regulatory filings Skyrizi